NANOMEDICINE IN THE PREVENTION AND TREATMENT OF LIVER FIBROSIS
Keywords:
Liver fibrosis, Nanomedicine, Nanoparticles, Targeted drug delivery, Hepatic stellate cells, Antifibrotic therapy, Liver disease, NanotechnologyAbstract
Hepatic fibrosis, caused by persistent liver damage, causes extracellular matrix protein buildup. Avoiding this issue may cause cirrhosis and liver failure. Nanomedicine for liver fibrosis prevention and treatment is novel and promising. Targeting antifibrotic medications, genes, and therapeutic agents to fibrotic liver tissues improves efficacy and reduces systemic toxicity. Liposomes, polymeric nanoparticles, lipid nanoparticles, and dendrimers improve drug stability, bioavailability, and release. Nanotechnology helps diagnose and monitor liver fibrosis early, allowing for appropriate treatment. Nanotechnology advances suggest that nanomedicine could revolutionize liver fibrosis prevention, diagnosis, and therapy, despite biocompatibility, safety, and clinical application concerns.
